Shield Therapeutics : Proactive Investor 1-2-1 Forum

Proactive Investor 1-2-1 Forum

8 April 2021

Tim Watts, CEO

Disclaimer

These slides have been prepared by Shield Therapeutics plc (the "Company") solely for your information and for use at a presentation for the purpose of providing background information on the Company, its business and the industry in which it operates. For the purposes of this notice, "presentation" means these slides, any oral presentation, any question and answer session and any written or oral material discussed or distributed during the presentation meeting.

This presentation has not been approved by the United Kingdom Listing Authority under the Prospectus Rules (made under Part VI of the Financial Services and Markets Act 2000, as amended) or otherwise, or by the London Stock Exchange plc. This presentation has not been independently verified and no representation or warranty, express or implied, is made or given by or on behalf of the Company or any of its subsidiaries or subsidiary undertakings, or any of such person's respective directors, officers, partners, employees, agents, affiliates or advisers, as to, and no reliance may be placed for any purpose whatsoever on the information or opinions contained in this presentation or on the completeness, accuracy or fairness thereof.

This presentation does not constitute or form part of, and should not be construed as, any offer, invitation or recommendation to purchase, sell or subscribe for any securities of the Company in any jurisdiction and neither the issue of this presentation nor anything contained herein shall form the basis of or be relied upon in connection with, or act as an inducement to enter into, any investment activity. This presentation does not purport to contain all of the information that may be required to evaluate any investment in the Company or any of its securities and should not be relied upon to form the basis of, or be relied on in connection with, any contract or commitment or investment decision whatsoever. This presentation is intended to present background information on the Company, its business and the industry in which it operates and is not intended to provide complete disclosure upon which an investment decision could be made. The merit and suitability of an investment in the Company should be independently evaluated and any person considering such an investment in the Company is advised to obtain independent advice as to the legal, tax, accounting, financial, credit and other related advice prior to making an investment.

No undertaking, representation, warranty or other assurance, express or implied, is or will be made or given by or on behalf of the Company or any of its subsidiary or subsidiary undertakings, or any of such person's respective directors, officers, partners, employees, agents, affiliates or advisers or any other person as to the accuracy or completeness of the information or opinions contained in this presentation and no responsibility or liability is accepted by any such person for any such information or opinions or for any errors, omissions or misstatements, negligent or otherwise, nor for any other communication written or otherwise. All information in this presentation is subject to verification, correction, completion and change without notice. None of the Company or any of its subsidiary or subsidiary undertakings, or any of such person's respective directors, officers, partners, employees, agents, affiliates or advisers, undertakes any obligation to amend, correct or update this presentation or to provide the recipient with access to any additional information that may arise in connection with it.

The statements contained in this presentation may include "forward-looking statements" that express expectations as to future events or results. Forward-looking statements can be identified by the use of forward-looking terminology, including the terms "believes", "estimates", "anticipates", "projects", "expects", "intends", "may", "will", "seeks" or "should" or, in each case, their negative or other variations or comparable terminology, or by discussions of strategy, plans, objectives, goals, future events or intentions. These statements are based on current expectations and involve risk and uncertainty because they relate to events and depend upon circumstances that may or may not occur in the future. There are a number of factors which could cause actual results or developments to differ materially from those expressed or implied by such forward-looking statements. Any of the assumptions underlying forward-looking statements could prove inaccurate or incorrect and therefore any results contemplated in forward-looking statements may not actually be achieved. Nothing contained in this presentation should be construed as a profit forecast or profit estimate. Investors and any other recipients of such communications are cautioned not to place reliance on any forward-looking statements. The Company undertakes no obligation to update or revise (publicly or otherwise) any forward-looking statement, whether as a result of new information, future events or other circumstances.

To the extent available, the data contained in this presentation has come from official or third party sources. Third party industry publications, studies and surveys generally state that the data contained therein have been obtained from sources believed to be reliable, but that there is no guarantee of the accuracy or completeness of such data. While the Company believes that each of these publications, studies and surveys has been prepared by a reputable source, the Company has not independently verified the data contained therein. In addition, certain of the data contained in this presentation come from the Company's own internal research and estimates based on the knowledge and experience of the Company's management in the market in which the Company operates. While the Company believes that such research and estimates are reasonable and reliable, they, and their underlying methodology and assumptions, have not been verified by any independent source for accuracy or completeness and are subject to change without notice. Accordingly, undue reliance should not be placed on any of the data contained in this presentation.

This presentation should not be copied or distributed by recipients and, in particular, should not be distributed by any means, including electronic transmission, to persons with addresses in the United States of America, Canada, Australia, South Africa or Japan, their possessions or territories or to any citizens thereof, or to any corporation, partnership or such entity created or organised under the laws thereof, or any other jurisdiction, where such distribution is unlawful. Any such distribution contrary to the above could result in a violation of the laws of such jurisdictions.

This presentation is confidential and is being supplied to you solely for your information and may not be reproduced, re-distributed or passed on, directly or indirectly, to any other person or published in whole or in part for any purpose. By attending the meeting where this presentation is made or by accepting a copy of this presentation, you agree to be bound by the limitations and restrictions set out above.

2

Company Overview

&

Investment Highlights

Overview of Shield Therapeutics:

Revenue Generating Pharmaceutical Company Focused on the Treatment of Iron Deficiency

• AIM-listedbiotech company (STX.L)
• Primary focus is on developing and commercializing Feraccru®/Accrufer®
• • A novel oral treatment for treating iron deficiency (ID) in adults
  • Approved in the USA and EU
  • £29m raised March 2021 to launch Accrufer® in the US
  • Commercialization out-licensed to:
  • • Norgine (Q4 2018) - Europe, Australia and New Zealand - £11m upfront received
    • ASK Pharma (Q1 2020) - China, Taiwan, Hong Kong and Macau - $11.4m upfront received
  • Patent protection until 2035
• Development pipeline
• • Late state asset - PT20 (phosphate binder to treat hyperphosphatemia)
  • Requires one phase 3 study to submit a MAA in Europe and NDA in the USA
• Organisation
• • Small but experienced management team in UK
  • • Corporate, non-US business development/alliance management, manufacturing & supply, clinical studies & regulatory affairs, IP
  • US commercial team established to launch Accrufer

Page 4

Investment Highlights (1/2)

• Iron deficiency is a large, diverse and undertreated market
• • Prevalent in multiple therapy areas - IBD, CKD, oncology, cardiology, women's health
  • Existing oral and IV therapies have significant drawbacks of poor tolerability/effectiveness (oral) and cost/ inconvenience/risk of iron overload (IV)
  • US market size
  • • ~10 million ID patients; ~5 million patients treated annually for IDA
    • >11 million US prescriptions annually
• There is a clear need for an effective, well-tolerated oral iron option
• Feraccru®/Accrufer® is a novel, oral, iron replacement therapy with patent protection to 2035
• Sales estimates generated internally and by management consultants/3rd parties support the potential for Accrufer® US sales to exceed $100m from the third year following launch and to reach $300m-$400m by years 5-6
• • $100m sales @90% gross margin and US costs $40m-$45m => $45m free cash flow
  • $300m sales @90% gross margin and US costs $40m-$45m => $225m free cash flow

Page 5